IDRA-21
Cognitive · Ampakine
Tier D
Bottom line
Read Off Label grades IDRA-21 as D (3.3/10) based on preclinical only evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Cortex Pharmaceuticals-era compound.
Typical use: No established human dosing — Research chem.
What this is
Cortex Pharmaceuticals-era compound. Primate cognition data (Baboons — Buccafusco) but no human trials. Typical ampakine concerns: seizure threshold lowering with chronic or high-dose use.
Mechanism
Benzothiadiazide ampakine; positive allosteric modulator of AMPA receptors; slows receptor desensitization; parent compound of the benzothiadiazide ampakine class
Dose & route
No established human dosing
Citations
- https://pubmed.ncbi.nlm.nih.gov/9216180/
- https://pubmed.ncbi.nlm.nih.gov/11164771/
- https://pubmed.ncbi.nlm.nih.gov/15582680/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does IDRA-21 work?
- Read Off Label rates the evidence for IDRA-21 as Preclinical only and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Cortex Pharmaceuticals-era compound.
- Is IDRA-21 safe?
- IDRA-21 has a unclear risk profile in published human data. Legal status: Research chem. This is not medical advice — see the disclaimer.
- What is the typical dose for IDRA-21?
- No established human dosing
- How does IDRA-21 work?
- Benzothiadiazide ampakine; positive allosteric modulator of AMPA receptors; slows receptor desensitization; parent compound of the benzothiadiazide ampakine class
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.